{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:14:07Z","timestamp":1783700047762,"version":"3.55.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Juvenile idiopathic arthritis (JIA) remains a clinical challenge when conventional and biological therapies fail.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>This report describes a case of highly refractory JIA and evaluates the efficacy of the Janus kinase (JAK) inhibitor upadacitinib, providing a potential therapeutic reference for difficult-to-treat pediatric autoimmune diseases. A 16-year-old female presented with a 3-year history of polyarticular swelling and pain that worsened over 1 month. Physical examination revealed extensive tenderness in the small joints of the hands, feet, and knees. Functional impairment was noted in the shoulder joints (restricted abduction and lifting) and wrist joints (limited flexion and extension). Laboratory results showed an erythrocyte sedimentation rate of 26\u2005mm\/h and a C-reactive protein level of 18.39\u2005mg\/L. Musculoskeletal ultrasound indicated grade 1 synovitis with effusion in the bilateral metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints, as well as both wrist joints. Effusion was also observed in the suprapatellar bursae of both knees. The patient's condition was classified as refractory, with prior failure of multiple lines of therapy, including conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), various biologic DMARDs (bDMARDs) (such as TNF, IL-6, and IL-1 inhibitors), and targeted synthetic DMARDs, such as tofacitinib. Following initiation of upadacitinib, the patient achieved marked clinical remission and improved joint mobility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Upadacitinib demonstrated potent efficacy in a pediatric patient with JIA who was nonresponsive to multiple bDMARDs and tofacitinib. These findings suggest that upadacitinib may be a viable salvage therapy for refractory JIA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1869089","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:31:06Z","timestamp":1783697466000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic efficacy of upadacitinib in refractory juvenile idiopathic arthritis: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Ningning","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Central Hospital of Dalian University of Technology","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Central Hospital of Dalian University of Technology","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingbing","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Central Hospital of Dalian University of Technology","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1002\/cpt.3441","article-title":"Extrapolation of upadacitinib efficacy in juvenile idiopathic arthritis leveraging pharmacokinetics, exposure-response models, and real-world patient data","volume":"116","author":"Qian","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.3390\/jcm12144695","article-title":"JAK inhibition in juvenile idiopathic arthritis (JIA): better understanding of a promising therapy for refractory cases","volume":"12","author":"Melki","year":"2023","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset still\u2019s disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.18176\/jiaci.0906","article-title":"Updated review on treatment of atopic dermatitis","volume":"33","author":"Armario-Hita","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1093\/rheumatology\/keaf085","article-title":"Experience with upadacitinib in refractory polyarticular juvenile idiopathic arthritis","volume":"64","author":"Atamy\u0131ld\u0131z U\u00e7ar","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/acr.25465","article-title":"Pharmacokinetics, efficacy, and safety of upadacitinib in pediatric patients with polyarticular-course juvenile idiopathic arthritis: an interim analysis of an open-label, phase 1 trial","volume":"77","author":"Brunner","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/s0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1494901","DOI":"10.3389\/fphar.2024.1494901","article-title":"JAK inhibitors: an evidence-based choice of the most appropriate molecule","volume":"15","author":"Antonioli","year":"2024","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12969-021-00514-4","article-title":"Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials","volume":"19","author":"Welzel","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/s0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1489092","DOI":"10.3389\/fmed.2024.1489092","article-title":"Corrigendum: efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries","volume":"11","author":"Vitale","year":"2024","journal-title":"Front Med (Lausanne)"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1869089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:31:07Z","timestamp":1783697467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1869089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":15,"alternative-id":["10.3389\/fped.2026.1869089"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1869089","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1869089"}}